drugset / Trial / NCT03948919

Fecal Transplant for Ulcerative Colitis

NCT03948919

Phase 1 Completed 26 enrolled University of Minnesota
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of this study is to evaluate the engraftment of donor microbiota with active ulcerative colitis (UC) following sequential fecal microbiota transplant (FMT). One key group of bacteria we are following are sulfate reducing bacteria (SRB). We plan to measure the relative abundance of SRB at baseline and after FMT. It is widely unknown if the microbiota in UC is dysfunctional and therefore perpetuates inflammation, or if the ongoing inflammation shapes the microbiota. We aim to determine if we can alter the microbiota in UC towards a healthy, more diverse microbiota resembling the donor using capsule FMT material.

Timeline

Start
2019-07-31
Primary completion
2023-11-03
Completion
2024-01-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fecal Microbiota Other / unclassified Oral

Indications